Management Team

Ian Wilson
Ian WilsonChief Executive Officer
Mr. Ian Wilson is the former CEO and CTO of Edinburgh Molecular Imaging Ltd, leading the development of novel optical imaging agents to improve cancer detection and surgery, and lung disease. He has held several roles at GE Healthcare between 1996 and 2013, including Portfolio and Strategy Manager and Head of Biology, with responsibility for management of GE Healthcare’s Molecular Imaging Agent Portfolio, in Cardiovascular, Oncology and Neurology, and strategic and tactical oversight. He had responsibility for supporting efficacy and regulatory studies required for the approval of new imaging agents. At Xstrahl Ltd, as CTO &COO, he was responsible for the oversight of the Radiotherapy commercial operation and manufacture oversight, including new product development. Mr. Wilson currently works and resides in the UK, though he travels extensively on behalf of ImaginAb. He is a graduate from University of Manchester with over 25 years’ experience in development of in vivo medical diagnostics and imaging medical devices.
David Fractor
David FractorChief Financial Officer
Mr. Fractor has served as our Chief Financial Officer on a part-time basis since May 2019. Prior to joining ImaginAb, Mr. Fractor was the Chief Financial Officer at ImmunoCellular Therapeutics, Ltd. From 2011 to 2019, an NYSE American listed company developing cancer immunotherapies. While at ImmunoCellular Therapeutics, Mr. Fractor participated in numerous financial transactions and was responsible for meeting all SEC reporting requirements.  Since 2003, Mr. Fractor has been a consultant providing financial consulting and strategic planning services, to a variety of companies in various industries. From 1999 through 2003, Mr. Fractor was the Chief Financial Officer of HemaCare Corporation, a publicly traded corporation which collects, manufactures, tests and distributes blood products to hospitals and provides blood services to patients in hospital settings on an outsourcing basis. Mr. Fractor previously was an audit manager at Deloitte and received his B.S. in Accounting from the University of Southern California in 1982. He is a certified public accountant and a member of AICPA and the California Society of CPA’s.
Ivan Plavec, PhD
Ivan Plavec, PhDChief Business Officer
Dr. Ivan Plavec is a president and founder of Ascellna Life Science Group, a consulting firm supporting life science companies with innovative technologies and products. Ivan has over twenty-five years of experience in the biotechnology and pharmaceutical industry in business development and research, and has held senior research positions at Novartis and Systemix, and executive and business development positions at BioSeek and Asterand. He has negotiated and closed over one hundred deals including complex drug discovery collaborations, technology-based collaborations, and product and technology licensing deals. He is author on over thirty peer-reviewed publications, has filed numerous patents and has a strong track record of scientific accomplishments and broad scientific experience in systems biology, human primary cells, small molecule screening and optimization, drug repositioning, expression vectors, gene therapy, stem cells, retroviruses, immunology and oncology. He holds a Ph.D. in Molecular Biology from the University of Zürich, Switzerland.
William Le
William LeVP, Operations
Mr. Le joined ImaginAb to lead the clinical development effort that includes Clinical Operations, Program and Project Management, CMC, Quality and Strategic Alliance Management. Mr. Le has 17+ years of industry experience in clinical research and cross-functional leadership in biotechnology and pharmaceutical drug development from Phase I–IV. Prior to joining ImaginAb, Mr. Le has held senior leadership role at Gradalis Inc., a start-up biotechnology company developing personalized molecular-based immuno-oncology therapies, functioning in a similar leadership role and capacity; and at Spectrum Pharmaceuticals where he managed and completed two registration programs that were submitted for New Drug Application (NDA), resulting in one being approved for the treatment of a rare disease. Mr. Le also spent years working at the major CRO’s before joining the industry Sponsor. Mr. Le obtained his Bachelor’s degree in Management from Oklahoma State University and his Master’s degree in Biotechnology Management from the University of Maryland University College.


Robert E. Reiter, MD
Co-Founder of ImaginAb, Consultant

Dr. Reiter is a Professor of Urology and Molecular Biology and Director of the Prostate Cancer Treatment and Research Program at the David Geffen School of Medicine at UCLA. He is currently the Principal Investigator of UCLA’s SPORE (Specialized Program in Research Excellence) program, a 12 million dollar research grant from the National Cancer Institute to develop new diagnostic and treatment options for men with prostate cancer. As co-developer of ImaginAb’s technology and Chief Medical Advisor, Dr. Reiter helps ensure high clinical impact and relevance by guiding the validation studies for ImaginAb’s clinical imaging pipeline. Dr. Reiter is a prominent figure …

> Read More

Brian Abeysekera, PhD

Dr. Brian Abeysekera, has more than 25 years of experience in radioisotope and radiopharmaceutical development, including production, radiochemistry, quality control, quality assurance and regulatory affairs activities in the United States and Canada. He is President of PharmaSPECT Inc, a company that provides cGMP and Manufacturing, Quality and Regulatory expertise to Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiopharmaceutical manufacturers. He previously served as Vice President, Manufacturing, Molecular Insight Pharmaceuticals …

> Read More

Thomas Digby
Consultant, Global IP Asset Management

Thomas is a US/Canadian intellectual property (IP) and transaction attorney with 22+ years’ experience in Global IP Asset Management. He provides worldwide strategic advice for IP portfolio assets to achieve licensing, M&A and commercialization objectives. From 2005-2016, Thomas was a member of the legal/IP department at Novartis (Cambridge, MA and Basel, Switzerland).